“Women at the Center of a New Renaissance” is the title of the National SIGO Congress, taking place from November 3 to 6 in Florence. This event is the main gathering for gynecology and obstetrics professionals in Italy.
This venue serves as the ideal platform for Polo GGB to announce an innovative test that will make a significant contribution to the field of gynecology.
This is the world’s first predictive genetic test specifically designed for vulvodynia, a poorly understood condition affecting many women.
Vulvodynia: A Highly Impactful Condition That Is Difficult to Diagnose
Vulvodynia is a complex, multifactorial disorder characterized by chronic vulvar pain, often accompanied by burning, itching, and discomfort that can severely impact quality of life.
Unfortunately, diagnosing this condition is often challenging and usually involves a long journey of examinations and medical visits, with a substantial impact on the well-being and peace of mind of those affected.
Early identification of individuals at risk, enabling preventive action through personalized therapies and interventions, has always been the true challenge in the clinical management of vulvodynia. SoReal will help to overcome this challenge.
A Predictive Test for Vulvodynia: Why It’s a Revolution
At the SIGO annual Congress, we will introduce an innovative approach based on the polygenic risk score technique, the foundation of SoReal.
This test provides doctors with a crucial tool for understanding genetic predispositions to vulvodynia and, above all, for guiding patients toward the most appropriate therapeutic treatment.
The Importance of a Multidisciplinary Approach in Managing Multifactorial Conditions
SoReal is the result of research conducted in collaboration with Prof. Filippo Murina, Head of the Lower Genital Tract Pathology Service at the “V. Buzzi” Hospital, University of Milan, and Scientific Director of the Italian Vulvodynia Association.
